Background {#Sec1}
==========

Hepatitis A is a vaccine preventable disease (VPD) caused by the hepatitis A virus (HAV). The hepatitis A virus is transmitted from person-to-person through the faecal-oral route primarily by ingestion of contaminated food or water and/or contact with infectious persons \[[@CR1], [@CR2]\]. Poor hygiene and sanitation pose the greatest risk for HAV infection, particularly in Low and Middle-Income Countries (LMICs) \[[@CR3]\]. Infection with HAV causes an immune response which is assessed by measurement of specific antibodies: immunoglobulin class M (IgM) anti-HAV antibodies and immunoglobin class G (IgG) anti-HAV antibodies \[[@CR4]\]. Anti-HAV IgM antibodies are detectable following acute infection and antibody titres usually decline to zero within 3--6 months \[[@CR5], [@CR6]\]. In contrast, anti-HAV IgG antibodies appear within 2--3 months after infection and persist for a long period of time conferring protective immunity against future infections \[[@CR2]\]. A majority of hepatitis A seroprevalence studies, therefore, often report anti-HAV IgG and not anti-HAV IgM seroprevalence data.

Common clinical symptoms of hepatitis A infection include jaundice, fever, malaise, anorexia, nausea and abdominal discomfort \[[@CR1], [@CR4]\]. Infection with HAV in early childhood is thought to be largely asymptomatic and results in the development of lifelong protective immunity \[[@CR4]\]. In contrast, infection with HAV after early childhood is associated with an increased risk of symptomatic, acute hepatitis A infection \[[@CR1], [@CR7], [@CR8]\]. The case fatality rate associated with acute hepatitis A in children and adults \< 50 years old ranges from 0.3 to 0.6%, while the case fatality rate in adults ≥50 years old ranges from 1.8 to 5.4% \[[@CR9]\]. The high costs associated with management of acute hepatitis A are well appreciated by healthcare providers. Hepatitis A patients typically miss several weeks of work or school and the costs of supportive medical care can be substantial \[[@CR4]\]. Therefore, vaccination against hepatitis A has been found to be cost-effective in many LMICs and should be prioritized in settings where hepatitis A is a public health concern \[[@CR10]\]. Routine hepatitis A vaccination policies can only be developed based on up-to-date and high-quality contextual evidence that includes the burden of the disease.

The World Health Organization (WHO) describes the epidemiology of hepatitis A according to HAV endemicity levels \[[@CR2]\]. Endemicity is measured by HAV seroprevalence; i.e. the proportion of people in the population with anti-HAV IgG antibodies \[[@CR11]\]. The levels of HAV endemicity are classified by the WHO as follows: high (≥ 90% IgG seroprevalence by 10 years of age), intermediate (≥ 50% IgG seroprevalence by 15 years of age, \< 90% IgG seroprevalence by 10 years of age), and low (≥ 50% IgG seroprevalence by 30 years of age, \< 50% IgG seroprevalence by 15 years of age) \[[@CR2]\]. The latest global review of HAV endemicity was published in 2010 and included epidemiological data from 1990 to 2005. The review classifies Africa as a high HAV endemic region \[[@CR12]\]. Since 2005, many African countries have made significant improvements in water, sanitation and developments in socio-economic status (SES). These improvements are likely to cause changes in the average age of first exposure and infection with HAV as well as in the prevalence of acute hepatitis A. Recent hepatitis A studies conducted in Africa, though few and far between, suggest that some regions on the continent could be experiencing a transition in hepatitis A epidemiology. Our aim in this review is to provide an up-to-date synthesis of hepatitis A epidemiology in Africa.

Rationale {#Sec2}
=========

The WHO does not recommend routine vaccination against hepatitis A in high endemic settings \[[@CR2]\]. As of 2018, no African country included routine hepatitis A vaccination as part of its' Expanded Programme on Immunisation (EPI). The WHO recommendation is that countries should routinely collect and review local factors and epidemiological data needed to guide the development of evidence-based recommendations on hepatitis A vaccination \[[@CR2]\]. To the best of our knowledge, an up-to-date, comprehensive synthesis of hepatitis A epidemiological data in Africa is lacking. Though there have been several primary studies on hepatitis A epidemiology published since 2005 in Africa, the review team is not aware of any recent publication that has synthesised data from this setting \[[@CR13]--[@CR16]\]. The development of effective public health control strategies against hepatitis A require optimal characterisation of the disease epidemiology. Therefore, this systematic review aims to fill the existing knowledge gap to guide considerations of development of public health strategies to control hepatitis A in the region.

Methods {#Sec3}
=======

Objectives {#Sec4}
----------

To describe the epidemiology of hepatitis A in Africa.

### Primary objectives {#Sec5}

To estimate the HAV seroprevalence (the prevalence of IgG anti-HAV antibodies) in AfricaTo estimate the prevalence of IgM anti-HAV antibodiesTo estimate the acute hepatitis A hospitalisation rate in AfricaTo estimate the acute hepatitis A case fatality rate in Africa

### Secondary objective {#Sec6}

To assess the impact of co-morbidities on hepatitis A epidemiology in Africa

Study eligibility criteria {#Sec7}
--------------------------

Published and unpublished case-series, case-control, cross-sectional, cohort studies as well as randomised control trial (RCTs) and non-randomised control trial (nRCTs) in any language that reported the epidemiology of hepatitis A in children \> 1 year of age as well as in adults in any African country were eligible for inclusion in this review. Studies were eligible for inclusion if they reported on any of the outcomes of this review, including seroprevalence of IgG anti-HAV antibody or prevalence of IgM HAV-antibody detection as well as hepatitis A disease incidence rates, hospitalisation rates, case fatality rates as well as co-infections.

Search strategy {#Sec8}
---------------

A combination of the following search terms (including the use of Medical Subject Headings (MESH)) was used: hepatitis A, acute hepatitis A, epidemiology, incidence, prevalence, morbidity, mortality, hospitalisation and case-fatality. An example of the search strategy as applied to PubMed is outlined in Table [1](#Tab1){ref-type="table"}. The following electronic databases were searched for relevant published literature: EBSCOhost, MEDLINE via PubMed, ScienceDirect via SciVerse, Scopus via SciVerse, Ovid Discovery and Google Scholar. Grey literature was sourced by consulting with expert researchers in the field and by searching the following grey literature repositories: OpenUCT, OpenGrey, MEDNAR and CORE. The literature search was initially performed in February 2018 and updated in December 2018.Table 1Search Strategy for PUBMEDQuery \#Search Query\#1hepatitis A \[MeSH Terms\] OR hepatitis A \[All Fields\] OR acute hepatitis A \[MeSH Terms\] OR acute hepatitis A \[All Fields\]\#2epidemiology \[MeSH Terms\] OR epidemiology \[All Fields\]\#3incidence \[MeSH Terms\] or incidence \[All Fields\]\#4prevalence \[MeSH Terms\] or prevalence \[All Fields\]\#5morbidity \[MeSH Terms\] OR morbidity \[All Fields\] OR hospitalisation \[MeSH Terms\] OR hospitalisation \[All Fields\] OR hospitalization \[MeSH Terms\] or hospitalization \[All Fields\]\#6mortality \[MeSH Terms\] OR mortality \[All Fields\] OR case-fatality \[MeSH Terms\] OR case-fatality \[All Fields\]\#7Africa \[MeSH Terms\] OR Africa \[All Fields\] OR Algeria \[All Fields\] OR Angola \[All Fields\] OR Benin \[All Fields\] OR Botswana \[All Fields\] OR Burkina Faso \[All Fields\] OR Burundi \[All Fields\] OR Cabo Verde \[All Fields\] OR Cameroon \[All Fields\] OR Central African Republic \[All Fields\] OR Chad \[All Fields\] OR Comoros \[All Fields\] OR Congo \[All Fields\] OR Cote d'Ivoire \[All Fields\] OR Djibouti \[All Fields\] OR Egypt \[All Fields\] OR Equatorial Guinea \[All Fields\] OR Eritrea \[All Fields\] OR Ethiopia \[All Fields\] OR Gabon \[All Fields\] OR Gambia \[All Fields\] OR Ghana \[All Fields\] OR Guinea \[All Fields\] OR Guinea-Bissau \[All Fields\] OR Kenya \[All Fields\] OR Lesotho \[All Fields\] OR Liberia \[All Fields\] OR Libya \[All Fields\] OR Madagascar \[All Fields\] OR Malawi \[All Fields\] OR Mali \[All Fields\] OR Mauritania \[All Fields\] OR Mauritius \[All Fields\] OR Morocco \[All Fields\] OR Mozambique \[All Fields\] OR Namibia \[All Fields\] OR Niger \[All Fields\] OR Nigeria \[All Fields\] OR Rwanda \[All Fields\] OR Sao Tome and Principe \[All Fields\] OR Senegal \[All Fields\] OR Seychelles \[All Fields\] OR Sierra Leone \[All Fields\] OR Somalia \[All Fields\] OR South Africa \[All Fields\] OR South Sudan \[All Fields\] OR Sudan \[All Fields\] OR Swaziland \[All Fields\] OR Tanzania \[All Fields\] OR Togo \[All Fields\] OR Tunisia \[All Fields\] OR Uganda \[All Fields\] OR Zambia \[All Fields\] OR Zimbabwe \[All Fields\]\#82005 \[PDAT\]: 2018 \[PDAT\]\#9\#1 AND \#2 AND \#3 AND \#4 AND \#Age of participants are included in search filter*Abbreviations*: *MeSH* Medical Subject Heading, *PDAT* Publication date

Data extraction {#Sec9}
---------------

Study characteristics and outcomes of interests were extracted from the included studies on a pre-designed data extraction form by two independent reviewers (JP and LA). Prior to use by the two reviewers, the reliability of the extraction form was assessed by piloting 10 randomly selected articles that met the inclusion criteria. The study resolved any disagreements in data extraction through consensus in consultation with BMK. In cases where studies were not available in English, google translate was used to translate the article to English \[[@CR17]\].

Data synthesis and analysis {#Sec10}
---------------------------

A random effects model was fitted to the study data as it includes estimates taken from a series of independently performed studies. Where heterogeneity between included studies was found to be low in meta-analyses (*I*^2^ \< 75), pooled outcome measures were reported with 95% confidence intervals for each respective outcome. Where heterogeneity was found to be high in meta-analyses (*I*^2^ ≥ 75), narrative reporting was used to describe the prevalence ranges for each respective outcome.

Risk of bias {#Sec11}
------------

Each included study was assessed for risk of bias and quality using the Hoy et al.*,* 2012 tool for observational studies \[[@CR18], [@CR19]\]. All risk of bias judgements were made by JP and LA. In case of disagreement in risk of bias and quality assessment, a final decision was made through consensus in consultation with BMK.

Reporting of review {#Sec12}
-------------------

This systematic review was registered with PROSPERO (registration number CRD42017079730) and the results are reported using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines checklist (Additional file [1](#MOESM1){ref-type="media"}) \[[@CR20]\].

Results {#Sec13}
=======

The initial database searches yielded 10,598 records, from which 4,334 duplicates were removed. No additional records were found when the search was updated in December 2018. A further 6,264 records were excluded following the screening of titles and abstracts (Fig. [1](#Fig1){ref-type="fig"}). The full-text of the remaining 121 records were screened, from which 30 records met the final inclusion criteria. A further two unpublished studies at the time of the search were obtained through personal communication with hepatitis A researchers \[[@CR11], [@CR21]\]. Since the time of reciept of these studies, they have since been published. Therefore, a total of 32 studies were included in this review. The included studies were conducted in 13 African countries, a majority of these being from the North, West and Southern regions of the continent (Fig. [2](#Fig2){ref-type="fig"}). Figure [2](#Fig2){ref-type="fig"} displays the geographic location of 27 of the included studies conducted on the African continent. Five of the 32 included studies (not shown in Fig. [2](#Fig2){ref-type="fig"}) reported hepatitis A data from expatriate communities (adults and children) from the African continent, living in Europe and North America \[[@CR22]--[@CR26]\].Fig. 1Flow diagram for selection of studies. PRISMA flow diagram of study selection processFig. 2Map of included studies. Map of studies included in this systematic review. Displays the geographical location of 28 of 32 included studies (4 excluded studies report hepatitis A data from Africa generally). Map adapted from Wikimedia Commons (<https://commons.wikimedia.org/wiki/File:BlankMap-Africa.svg>)

Twenty-three of the included studies were cross-sectional studies (Table [2](#Tab2){ref-type="table"}). A majority of the included studies were conducted in the public healthcare sectors of lower-middle income countries. Of the 32 included studies, 17 provided data on anti-HAV IgG alone (referred to hereon as HAV seroprevalence), 11 provided data on anti-HAV IgM alone (referred to hereon as IgM anti-HAV seroprevalence) and 4 studies provided data together for IgG anti-HAV and IgM anti-HAV seroprevalence. Our analyses categorize the included studies according to the population age-groups \[children & adolescents (1 to 18 years of age), adults (\> 18 years of age) and all ages (1 to 99 years of age)\], of which children and adolescent populations were most commonly reported on (56% of included studies). Measurement of the anti-HAV antibodies was assessed using ELISA assays for both IgG and IgM positivity in all studies. Real time PCR (RT-PCR) was used in 4 studies, in addition to the ELISA assay (Table [3](#Tab3){ref-type="table"}). Details on the assay detection limits were missing from all included studies.Table 2Characteristics of studies included in the reviewAuthor, Year (Citation)Study DesignYear(s) of Data CollectionCountryPopulationSample Size (n)Outcome MeasuresStudy ObjectiveAbdulla et al., 2010 \[[@CR22]\]Cross-sectional2006 to 2008General AfricaChildren & adolescents29IgGTo determine the prevalence of acute hepatitis A virus infection and immunity among internationally adopted childrenAfegbua et al., 2013 \[[@CR27]\]Cross-sectional2009NigeriaChildren & adolescents403IgGTo determine seroprevalence of HAV among schoolchildren and adolescents in Kaduna State and identify factors associated with seropositivityAl-Aziz et al., 2008 \[[@CR28]\]Cohort2008EgyptChildren & adolescents296IgGTo determine the seroprevalence of HAV antibodies among group of childrenBlanchi et al., 2014 \[[@CR23]\]Cohort2009 to 2012General AfricaChildren146IgMTo describe infectious diseases in internationally adopted childrenBonney et al., 2013 \[[@CR29]\]Cross-sectional2008 to 2011GhanaAll ages285IgMTo determine if viral hemorrhagic fevers and viral hepatitides contribute to hospital morbidity in the Central and Northern parts of GhanaBouskraoui et al., 2009 \[[@CR30]\]Cross-sectional2005 to 2006MorroccoChildren & adolescents150IgGTo assess the prevalence of viral hepatitis A infection in febrile icteric children and to examine the main risk factors of transmissionBurrous et al., 2010 \[[@CR31]\]Cross-sectional2006 to 2008MorroccoChildren & adolescents129IgMTo assess the prevalence of viral hepatitis A infection in febrile icteric children and to examine the main risk factors of transmissionEl-Karasksy et al., 2008 \[[@CR32]\]Cohort2005EgyptChildren & adolescents172IgGTo determine the prevalence of anti-hepatitis A virus antibodies among 172 children with chronic liver diseaseEllis et al., 2008 \[[@CR33]\]Cohort2008MaliChildren36IgMPhase 1 study in Malian children of the blood stage malaria vaccineEnoch et al., 2019 \[[@CR21]\]Cross-sectional2009 to 2015South AfricaChildren482IgGTo determine the seroprevalence of hepatitis A infection in the Western Cape Province of South AfricaForbi et al., 2012 \[[@CR34]\]Cohort2012CameroonChildren78IgMTo undertake genetic analysis of the hepatitis A virus associated with cases of acute diarrhea among children under five in CameroonForbi et al., 2012_2 \[[@CR35]\]Cross-sectional2006NigeriaAdults114IgMTo investigate HAV strains among apparently healthy adult Nigerian subjectsGuenifi et al., 2017 \[[@CR36]\]Cross-sectional2010 to 2011AlgeriaChildren1061IgGTo estimate the seroprevalence of hepatitis A virus infection in the district of SetifIkobah et al., 2015 \[[@CR37]\]Cross-sectional2012NigeriaChildren & adolescents406IgGTo determine the seroprevalence and predictors of viral hepatitis A in children aged 1 to 18 yearsJablonka et al., 2017 \[[@CR38]\]Cross-sectional2015General AfricaAll ages55IgGTo determine the seroprevalence of anti-HAV IgG in refugees in GermanyKlouwenberg et al., 2011 \[[@CR39]\]Cohort2011KenyaChildren222IgMTo determine the temporal pattern of a co-infection of *P. falciparum* malaria and acute HAV in a cohort of Kenyan children under the age of fiveLopes et al., 2017 \[[@CR40]\]Cross-sectional2015South AfricaAll ages300IgGTo determine the seroprevalence of HAV and HEV antibodies in blood donors giving at the Western Province Blood Transfusion ServiceLouati et al., 2009 \[[@CR41]\]Cross-sectional2007TunisiaAdults376IgGTo assess hepatitis A virus seroprevalence in blood donors from South Tunisia in two periods; 200 and 2007Majori et al., 2008 \[[@CR26]\]Cross-sectional2008General AfricaAll ages182IgG & IgMTo assess the seroprevalence of viral hepatitis infections in sub-Saharan immigrants living in ItalyMazanderani et al., 2018 \[[@CR11]\]Cross-sectional2005 to 2015South AfricaAll ages501083IgG & IgMTo assess seroprevalence rates among specimens tested for HAV serology within South Africa's public health sectorMphaka et al., 2016 \[[@CR42]\]Cross-sectional2016South AfricaChildren & adolescents46IgMTo respond to an increase in blood samples testing positive for HAV IgMMurchiri et al., 2012 \[[@CR43]\]Cross-sectional2007 to 2008KenyaAdults100IgMTo determine seroprevalence of HAV, HBV HCV and HEV among patients with acute hepatitis in Nairobi KenyaNagu et al., 2008 \[[@CR44]\]Cross-sectional2006TanzaniaAdults260IgMTo determine the prevalence and predictors of viral hepatitis co-infection among HIV-infected individuals presenting at the HIV care and treatment clinics in the countryNeffatti et al., 2017 \[[@CR45]\]Cross-sectional2014 to 2015TunisiaAdults216IgGTo supplement lacking data on hepatitis A and E from rural areas of South TunisiaOgefere et al., 2016 \[[@CR46]\]Cross-sectional2016NigeriaAll ages200IgMTo determine the seroprevalence of anti-HAV IgM in an at-risk population in Benin City and to identify the social, demographic and other risk factorsRaabe et al., 2014 \[[@CR24]\]Cross-sectional2014General AfricaChildren656IgMTo assess the need to recommend routine HAV vaccination in internationally adopted childrenRabenau et al., 2010 \[[@CR47]\]Cohort2007LesothoAdults205IgGTo screen international adoptees for acute HAV infectionRezig et al., 2008 \[[@CR48]\]Cross-sectional2008AlgeriaChildren & adolescents3357IgGTo assess the seroprevalence of coinfecting viruses in a cohort of 205 HIV-infected individualsSmahi et al., 2009 \[[@CR49]\]Cross-sectional2006AlgeriaChildren252IgGTo determine the seroprevalence of hepatitis A and E infectionsSule et al., 2013 \[[@CR50]\]Cross-sectional2010 to 2011NigeriaAll ages91IgGTo determine the prevalence of anti-hepatitis A virus IgG antibody and associated factors among residents of OsogboTantawy et al., 2012 \[[@CR51]\]Case-control2009 to 2010EgyptChildren & adolescents182IgGTo evaluate the seroprevalence of hepatitis A in Egyptian patients with haemophilia ATraore et al., 2012Cross-sectional2010 to 2012Burkina FasoAdults91IgG & IgMTo assess the seroprevalence of antibodies to both HAV and HEV in central Burkina Faso in the absence of a recorded hepatitis epidemic*Abbreviations*: *HAV* Hepatitis A virus, *IgG* Immunoglobin class G, *HBV* Hepatitis B virus, *HCV* Hepatitis C virus, *HEV* Hepatitis E virusTable 3Assays used in included studiesAuthor, YearAssayBrandAbdulla et al., 2010 \[[@CR22]\]ELISADiaSorinAfegbua et al., 2013 \[[@CR27]\]ELISAAsia-lion BitechnologyAl-Aziz et al., 2008 \[[@CR28]\]ELISADiaSorinBlanchi et al., 2014 \[[@CR23]\]SerologyNRBonney et al., 2013 \[[@CR29]\]RT-PCRRealStarBouskraoui et al., 2009 \[[@CR30]\]ELISANRBurrous et al., 2010 \[[@CR31]\]ELISADiaSorinEl-Karasksy et al., 2008 \[[@CR32]\]ELISADiaSorinEllis et al., 2008 \[[@CR33]\]Serology & ALT levelsNREnoch et al., 2019 \[[@CR21]\]ELISASiemensForbi et al., 2012 \[[@CR34]\]RT-PCRApplied BiosystemsForbi et al., 2012_2 \[[@CR35]\]RT-PCRNRGuenifi et al., 2017 \[[@CR36]\]ELISARocheIkobah et al., 2015 \[[@CR37]\]EIADRG International Inc.Jablonka et al., 2017 \[[@CR38]\]ELISAAbbott ARCKlouwenberg et al., 2011 \[[@CR39]\]ELISABioChainLopes et al., 2017 \[[@CR40]\]ELISAAbbott ARCLouati et al., 2009 \[[@CR41]\]ELISADiaSorinMajori et al., 2008 \[[@CR26]\]ELISAAbbott ARCMazanderani et al., 2018 \[[@CR11]\]SerologyNRMphaka et al., 2016 \[[@CR42]\]SerologyNRMurchiri et al., 2012 \[[@CR43]\]ELISANRNagu et al., 2008 \[[@CR44]\]ELISAAdaltisNeffatti et al., 2017 \[[@CR45]\]RT-PCRWantaniOgefere et al., 2016 \[[@CR46]\]SerologyQingdao High-top BiotechRaabe et al., 2014 \[[@CR24]\]SerologyN/ARabenau et al., 2010 \[[@CR47]\]ELISAAxSYM MEIARezig et al., 2008 \[[@CR48]\]ELISABio-RadSmahi et al., 2009 \[[@CR49]\]SerologyNRSule et al., 2013 \[[@CR50]\]ELISADiaSorinTantawy et al., 2012 \[[@CR51]\]ELISADiaSorinTraore et al., 2012ELISADiaSorin*Abbreviations*: *NR* Not reported, *ELISA* Enzyme-linked immunosorbent assay, *RT-PCR* Reverse transcription polymerase chain reaction, *EIA* Competitive enzyme immunoassay, *ALT* Alanine aminotransferase

HAV seroprevalence in Africa from 2008 to 2018 {#Sec14}
----------------------------------------------

Heterogeneity was high (*I*^*2*^ = 99.21%) among the 15 studies pooled for analysis of IgG seroprevalence in all age groups. This was not surprising considering the diversity of the included studies, thus we categorized the analysis of HAV seroprevalence by age-groups (Fig. [3](#Fig3){ref-type="fig"}). The estimated average of the reported HAV seroprevalence for children and adolescents among included studies was 57.0% (ES = 0.57; 95% CI = 0.40, 0.73) as compared to compared to 95.0% (ES = 0.98; 95% CI = 0.85, 1.00) for adults.Fig. 3HAV seroprevalence by population group in africa, 2008-2018

Data reported by Mazanderani et al.*,* (2018) presented a unique opportunity to further explore of HAV seroprevalence by age-groups in South Africa from 2005 to 2015 (Fig. [4](#Fig4){ref-type="fig"}). The data displayed in Fig. [4](#Fig4){ref-type="fig"} shows that HAV seroprevalence for children, adolescents \< 15 years old remained below 90% for any given year between 2005 and 2015. Additionally, Fig. [4](#Fig4){ref-type="fig"} shows that HAV seroprevalence for adolescents ≥ 15 and adults \< 20 reduced from its highest in 2011 (92.8%) to 83.5% in 2015.Fig. 4HAV seroprevalence estimates by age-group in South Africa, 2005-2015

IgM anti-HAV seroprevalence in Africa from 2008 to 2018 {#Sec15}
-------------------------------------------------------

We have used IgM anti-HAV seroprevalence as a marker for acute hepatitis A infection in this review \[[@CR52]\]. Pooled acute hepatitis A prevalence for 2008 to 2018 showed high heterogeneity (*I*^*2*^ = 98.1%) (Fig. [5](#Fig5){ref-type="fig"}**).** An outlier in the data (Burros et al., 2010) reported acute hepatitis A prevalence in a population of febrile icteric children \[91.0% (ES = 0.91; 95% CI = 0.85, 0.96)\] and removed from the analysis. With removal of the outlier from the dataset, the average annual acute hepatitis A prevalence was reported to be approximately 5.0% (ES = 0.05; 95% CI = 0.03, 0.08).Fig. 5IgM anti-HAV seroprevalence in Africa, 2008-2018

We further explored the age-related risk of acute hepatitis A infection in Africa. When assessing IgM anti-HAV seroprevalence by age-group, the heterogeneity between studies was found to be relatively low (*I*^2^ = 74.73) (Fig. [6](#Fig6){ref-type="fig"}). The estimated average IgM anti-HAV seroprevalence for children and adolescents among included studies was 7.0% (ES = 0.07; 95% = 0.04, 0.12) (Fig. [6](#Fig6){ref-type="fig"}). The estimated average IgM anti-HAV seroprevalence for adults among included studies was 5.0% (ES = 0.05; 95% = 0.03, 0.07) (Fig. [6](#Fig6){ref-type="fig"}). The similarity in the estimated IgM anti-HAV seroprevalences among children, adolescents and adults is not expected in a high HAV endemic region such as Africa.Fig. 6IgM HAV seroprevalence by population group in Africa, 2008-2014

IgM anti-HAV seroprevalence in South Africa {#Sec16}
-------------------------------------------

Data reported by Mazanderani et al.*,* (2018) allowed us to further explore age-related IgM anti-HAV seroprevalence in South Africa, a country with no routine hepatitis A vaccination \[[@CR11]\]. Figure [7](#Fig7){ref-type="fig"} shows the annual IgM anti-HAV seroprevalence by age-group between 2005 and 2015 in South Africa, in which the overall IgM anti-HAV seroprevalence was found to be highest in children \< 15 years of age. Acute hepatitis A infection rates over the decade for age groups \< 10 years of age and 10 to 14 years of age were approximately 16.5 and 15.0%, respectively. The prevalence of acute hepatitis A in South Africa appeared to increase for all reported age-groups between 2005 and 2015.Fig. 7IgM anti-HAV seroprevalence estimates by age-group in South Africa, 2005-2015

Methodological quality {#Sec17}
----------------------

For each included study, risk of bias and quality assessments were conducted using the Hoy et al.*,* risk of bias tool that examines internal and external validity of observation studies. Studies were judged as having 'low risk' if scored 8--10, 'moderate risk' if scored 5--7 and 'high risk' if scored 0--5. Scores were assigned by two (JP and LA) reviewers and the reasons for the assigned score was provided (Table [4](#Tab4){ref-type="table"}). The scores assigned by the two reviewers we then compared. Where the assigned score made by JP and LA differed, these differences were resolved through consensus in consultation with BMK. For any score below 10, a descriptive summary of the information that influenced our judgments was provided. Majority of the studies were scored either 10 or 8 due to one or a combination of the following reasons: 1) selection of the research location was not justified; 2) Selection of study participants was not generalizable to the entire population; 3) Selection bias may be present.Table 4Risk of Bias assessment for included studiesAuthor, YearRisk of BiasHoy et al. tool ScoreScore DescriptionAbdulla et al., 2010 \[[@CR22]\]Low10Afegbua et al., 2013 \[[@CR27]\]Low81) Selection of research location was convenience and not justified as generalizable to entire population; 2) No description of how survey was conducted is givenAl-Aziz et al., 2008 \[[@CR28]\]Low91) Selection of research location was convenience and not justified as generalizable to entire populationBlanchi et al., 2014 \[[@CR23]\]Low10Bonney et al., 2013 \[[@CR29]\]Low91) Selection of research location was convenience and not justified as generalizable to entire populationBouskraoui et al., 2009 \[[@CR30]\]Low10Burrous et al., 2010 \[[@CR31]\]Low10El-Karasksy et al., 2008 \[[@CR32]\]Low91) Selection of research location was convenience and not justified as generalizable to entire populationEllis et al., 2008 \[[@CR33]\]Low10Enoch et al., 2019 \[[@CR21]\]Low10Forbi et al., 2012 \[[@CR34]\]Low91) Selection of research location was convenience and not justified as generalizable to entire populationForbi et al., 2012_2 \[[@CR35]\]Low91) Selection of research population was not justified as generalizable to entire populationGuenifi et al., 2017 \[[@CR36]\]Low91) Selection of research population was not justified as generalizable to entire populationIkobah et al., 2015 \[[@CR37]\]Low91) Selection of total anti-HAV antibody testing may confound resultsJablonka et al., 2017 \[[@CR38]\]Low10Klouwenberg et al., 2011 \[[@CR39]\]Low91) Selection of research population was not justified as generalizable to entire populationLopes et al., 2017 \[[@CR40]\]Low91) Years of data collection not described in publicationLouati et al., 2009 \[[@CR41]\]Low10Majori et al., 2008 \[[@CR26]\]Low91) Selection of research population was not justified as generalizable to entire populationMazanderani et al., 2018 \[[@CR11]\]Low10Mphaka et al., 2016 \[[@CR42]\]Low81) Selection of research population was not justified as generalizable to entire population; 2) No random selection or census undertakenMurchiri et al., 2012 \[[@CR43]\]Low81) Purposive sampling leads to selection bias; 2) Selection of research population was not justified as generalizable to entire populationNagu et al., 2008 \[[@CR44]\]Low91) Selection of research population was not justified as generalizable to entire populationNeffatti et al., 2017 \[[@CR45]\]Low10Ogefere et al., 2016 \[[@CR46]\]Low91) Sampling method may have led to selection biasRaabe et al., 2014 \[[@CR24]\]Low91) Selection of research population was not justified as generalizable to entire populationRabenau et al., 2010 \[[@CR47]\]Low91) Selection of research population was not justified as generalizable to entire populationRezig et al., 2008 (55)Low10Smahi et al., 2009 (56)Low10Sule et al., 2013 (57)Low91) Selection of research population was not justified as generalizable to entire populationTantawy et al., 2012 (58)Low10Traore et al., 2012 (59)Low91) Selection of research location was convenience and not justified as generalizable to entire population

Discussion {#Sec18}
==========

This systematic review evaluated the epidemiology of hepatitis A in participants \> 1 year of age in Africa. The main findings of the review include: 1) the reported HAV seroprevalence data suggests that Africa, as a whole, should not be considered as a high HAV endemic region; 2) the IgM anti-HAV seroprevalence data showed similar risk of acute hepatitis A infection among all age-groups; 3) South Africa could be experiencing a possible transition from high to intermediate HAV endemicity. The results of this review were limited due to lack of detailed age-grouped data from the included studies. Additionally, no included review reported data on the hospitalisation and case fatality rates or co-morbidities occurring with acute hepatitis A which did not allow for the objectives of the paper to be met fully.

Only 13 (24%) out of 54 countries in Africa contributed to the data synthesized in this review. Furthermore, the data included in this review was collected mainly in hospital settings as opposed to from community surveys. A recent study on trends of childhood immunisation research in Africa reported lack of hepatitis A research on the continent \[[@CR53]\]. Based on these findings, we believe that more up-to-date research on hepatitis A epidemiology in Africa is needed and will be critical to generate evidence needed to re-think hepatitis A control strategies in the region.

Although limited, the HAV seroprevalence data in this review appear to meet the WHO's definition of intermediate HAV endemic setting (\< 90% IgG seroprevalence by 10 years of age and ≥ 50% IgG seroprevalence by 15 years of age) \[[@CR54]\]. The reported HAV seroprevalence estimates for children and adolescents age-groups indicate that the presumed "natural immunisation" during the early childhood is not sufficient to imply high HAV endemicity for the entire continent. Secondly, the reported similarity of IgM anti-HAV seroprevalence among children and adolescents compared with adults was a surprising finding as we expected lower IgM anti-HAV seroprevalence in adults than children due to prior exposure in a high endemic setting. A recent study in China and conducted in a setting undergoing a hepatitis A epidemiological transition, adults aged 20 years and older showed higher disease incidence than children \[[@CR55]\]. Thus, our findings corroborate the notion of a HAV epidemiological transition in the African region.

Current global recommendations on hepatitis A vaccination appear to take African countries as homogeneous settings \[[@CR54]\]. Our review results showed a large spread in HAV seroprevalence rates as well as IgM anti-HAV seroprevalence rates across the continent. This indicates the heterogeneity of hepatitis A epidemiology, and highly likely, the epidemiology of other VPDs among African countries. For example, in South Africa where comprehensive dataset was available, we reported an increase in IgM anti-HAV seropositivity among all age groups from 2005 to 2015. These results indicate that South Africa is most likely transitioning from high to intermediate endemicity. Previous classifications of South Africa as a high endemic region have been based on limited data published between 1986 and 2002 \[[@CR56]\]. This data showed variable HAV seroprevalence rates that were dependent on SES. High HAV seropositivity rates were reported in low SES groups, while high SES groups that were less represented in the data showed low HAV seropositivity rates. Given this and the gradual social economic improvements in South Africa since the collapse of apartheid, it is likely that the HAV epidemiological transition in South Africa has been taking place even before 2005. It would be irrational to extrapolate findings from South Africa to all other African countries as Hepatitis A epidemiology is highly influenced by economic as well as healthcare developments \[[@CR57]\]. Our findings suggest that African countries with similar SES developments as South Africa should prioritize generating evidence to guide recommendations on introducing routine immunisation against the disease.

The results of this review must be interpreted with caution due to several limitations. Firstly, the included studies have significant sociocultural, economic and environmental diversity. Secondly, due to the fact that only 13 of 54 countries in Africa contributed to the data synthesized in this review, we were not able to present data for all sub-regions of the continent or by country income category. Thirdly, as data included in this review were collected mainly in hospital settings as opposed to from community surveys, we were unable to stratify our results to urban versus rural areas to assess whether hygiene and sanitation affect the current epidemiology of HAV in Africa. Lastly, although trends in publication of the immunisation research is growing, a lot of research work in Africa still remains unpublished and access to such information is limited \[[@CR58]\]. Regardless of these limitations, it is noteworthy to mention that the majority of included studies focused on hepatitis A data in childhood and adolescent populations, which may attest to the anecdotal evidence that children and adolescents are increasingly at risk for acute hepatitis A infection in Africa.

The results of this paper may be an over-estimate of HAV seroprevalence for the general population in Africa as those seeking private healthcare services were not included in this review. Populations seeking private healthcare services are more likely to be of higher social economic status. Higher social economic populations have access to optimal sanitation and are likely to show lower HAV seroprevalence although some may be vaccinated against the disease \[[@CR27]\]. Furthermore, the extent of HAV vaccine use in the private sector of Africa is unknown. Future research should include populations seeking both private and private healthcare. Measurement of both IgG and IgM as immunological outcomes should be incorporated in future studies as well as details of the assay detection limits used. Additional missing data such as morbidity, co-morbidity and mortality due to hepatitis A disease should be a research priority. Collectively, complete and high-quality hepatitis A epidemiology data would allow for better pooling of results and meta-analyses. The review team also encourages future studies to incorporate mathematical modelling where the data permits as such an approach could possibly assist health policy decision-makers to better design hepatitis A control strategies in Africa.

Conclusion {#Sec19}
==========

This systematic review aimed to generate up-to-date epidemiological data of hepatitis A in Africa with the aim of providing data to better inform hepatitis A public health control measures in the region. We successfully addressed the aim of the study although data on hospitalization, case fatality rates and co-morbidity was missing. With no current routine use of hepatitis A vaccines on the African continent, quality epidemiological data that is currently missing should be compiled and priority be given in re-assessing the current hepatitis A control strategies in the region to prevent possible disease outbreaks in the future.
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EPI

:   Expanded Programme on Immunisation

HAV

:   Hepatitis A virus

IgG

:   Immunoglobin class G antibodies

IgM

:   Immunoglobulin class M antibodies

LMICs

:   Low and Middle-Income Countries

MeSH

:   Medical Subject Headings

nRCT

:   non-Randomised Control Trial

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-analyses

RCT

:   Randomised Control Trial

RT-PCR

:   Real time PCR

SES

:   Socio-Economic Status

VPD

:   Vaccine Preventable Disease

WHO

:   World Health Organization
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